Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz

Blood (2023) 142 (Supplement 1): 187.

https://doi.org/10.1182/blood-2023-187759

Published: 2023

Journal Articles

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Blood (2023) 142 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2023-179547

Published: 2023

Journal Articles

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma

Joseph Schroers-Martin, Jurik A Mutter, Mohammad Shahrokh Esfahani, Florian Scherer, Joanne Soo, Stefan K. Alig, David M. Kurtz, Takeshi Sugio, Cédric Rossi, Benoit Tessoulin, Mari Olsen, Chih Long Liu, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 528.

https://doi.org/10.1182/blood-2023-187116

Published: 2023

Journal Articles

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Takeshi Sugio, Navika Shukla, Michael S Khodadoust, Monica Nesselbush, Koji Kato, Stefan K. Alig, Jan Boegeholz, Joseph Schroers-Martin, Mohammad Shahrokh Esfahani, Jurik A. Mutter, Andrea Garofalo, Soyeong Jun, Mark P. Hamilton, Cédric Rossi, Mari Olsen, Chih Long Liu, Koichi Akashi, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2023-180492

Published: 2023

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

Journal Articles

Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma

Shengqin Su, Ajay Subramanian, Timothy Flerlage, Jamie E. Flerlage, Stefan K. Alig, Everett J. Moding, Richard T. Hoppe, Ranjana H. Advani, Yasodha Natkunam, Ash A. Alizadeh, Michael S. Binkley

Blood (2023) 142 (Supplement 1): 3016.

https://doi.org/10.1182/blood-2023-180288

Published: 2023

Journal Articles

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Blood (2023) 142 (Supplement 1): 360.

https://doi.org/10.1182/blood-2023-182522

Published: 2023

Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser

Blood (2023) 142 (Supplement 1): 225.

https://doi.org/10.1182/blood-2023-181007

Published: 2023

Journal Articles

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Ákos Nagy, Bence Bátai, Gregory Hogan, Jacob J. Chabon, Mikayla Troke, Lance Riley, Andre Schultz, Sandra Close, Maximilian Diehn, Donát Alpár, Botond Timár, Ash A. Alizadeh, David M. Kurtz, Csaba Bödör

Blood (2023) 142 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2023-189824

Published: 2023

Journal Articles

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Jurik A Mutter, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Stefan K. Alig, Mark P. Hamilton, Brian J. Sworder, Benoit Tessoulin, Jan Boegeholz, Timothy Flerlage, Jamie E. Flerlage, Michael S. Binkley, Takeshi Sugio, Cédric Rossi, Mari Olsen, Chih Long Liu, Steven Le Gouill, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 245.

https://doi.org/10.1182/blood-2023-186853

Published: 2023

Journal Articles

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Cédric Rossi, Jan Boegeholz, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Mari Olsen, Xiaoman Kang, David M. Kurtz, Takeshi Sugio, Mark P. Hamilton, Marc Andre, Rene-Olivier Casasnovas, Luc Matthieu Fornecker, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2023-178257

Published: 2023

Journal Articles

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Mark Roschewski, Liza Lindenberg, Esther Mena, Rahul Lakhotia, Christopher Melani, Seth M. Steinberg, Andre Schultz, Gregory Hogan, Jake J. Chabon, Sandra Close, Maximilian Diehn, Brian J. Sworder, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson

Blood (2023) 142 (Supplement 1): 192.

https://doi.org/10.1182/blood-2023-180007

Published: 2023

Journal Articles

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David M. Kurtz, Gregory Hogan, Andre Schultz, Jacob J. Chabon, Ash A. Alizadeh, Karin Havenith, Sara Samari, Tim Kopotsha, Luqiang Wang, Yajuan Qin, Ying Wang, Serafino Pantano

Blood (2023) 142 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2023-179977

Published: 2023

Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim

Blood (2023) 142 (Supplement 1): 69.

https://doi.org/10.1182/blood-2023-187650

Published: 2023

Journal Articles

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Blood (2023) 141 (21): 2576–2586.

https://doi.org/10.1182/blood.2022019254

Published: 2023

Includes: Supplemental data

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Blood (2022) 140 (Supplement 1): 1295–1296.

https://doi.org/10.1182/blood-2022-164744

Published: 2022

Journal Articles

Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma

Irl Brian Greenwell, Jeffrey M. Switchenko, Alexander F.M. Craig, Ash A. Alizadeh, Pamela B. Allen, Alicia Escobar, Kelly Valla, Aseala Abousaud, Priya Parikh, Danielle Roberts, Jessica J. Neely, Alexandra Palmer, Kristie A. Blum, Jonathon B. Cohen, Marcela Algave

Blood (2022) 140 (Supplement 1): 9373–9374.

https://doi.org/10.1182/blood-2022-167947

Published: 2022

Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak

Blood (2022) 140 (Supplement 1): 2378–2380.

https://doi.org/10.1182/blood-2022-162150

Published: 2022

NARROW

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Genomic profiling for clinical decision making in lymphoid neoplasms

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only